Who Paid My Doc
Laurice Yang
Clinical Neurophysiology Stanford, CA Medical Doctor
NPI 1053545822 CMS profile 707023
300 Pasteur Dr, Stanford, CA 94305
General payments
$924
Research payments
$800
Ownership & investment interest
$0
Research they led as principal investigator
$476,525
Through program year 2025, Laurice Yang of Stanford, CA is reported in the CMS Open Payments database as having received $924 across 6 general payments and $800 in research payments paid to them. Separately, studies naming them as principal investigator received $476,525 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 54th percentile of Clinical Neurophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $701 | 5 | |
| 2020 | Research | $800 | 1 | |
| 2019 | General | $223 | 1 |
Beside peers
- Laurice Yang
- Clinical Neurophysiology median
- Middle half of Clinical Neurophysiology
- National median
In program year 2025, general payments to Laurice Yang were reported at $701. Among 259 Clinical Neurophysiology profiles paid that year, the median was $435 and the middle half received between $121 and $1,917.
Show as a table
| Year | Laurice Yang | Clinical Neurophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $223 | $306 | $88–$1,636 | $163 |
| 2020 | $0 | $299 | $85–$1,847 | $114 |
| 2021 | $0 | $325 | $96–$2,308 | $132 |
| 2022 | $0 | $395 | $106–$1,957 | $149 |
| 2023 | $0 | $388 | $120–$1,718 | $160 |
| 2024 | $0 | $471 | $137–$1,931 | $164 |
| 2025 | $701 | $435 | $121–$1,917 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
619
Drug cost
$103,754
Branded share of claims
65.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rytary Carbidopa/Levodopa | Brand | 34 | $66,097 | |
| Rasagiline Mesylate | Generic | 38 | $13,708 | |
| Carbidopa-Levodopa Carbidopa/Levodopa | Brand | 172 | $9,888 | |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | Brand | 102 | $4,766 | |
| Amantadine Amantadine Hcl | Brand | 55 | $2,546 | |
| Ropinirole Er Ropinirole Hcl | Brand | 14 | $2,345 | |
| Gabapentin | Generic | 55 | $1,351 | |
| Rivastigmine Rivastigmine Tartrate | Brand | 20 | $969 | |
| Clonazepam | Generic | 60 | $541 | |
| Pregabalin | Generic | 22 | $414 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 20 billing codesPaid by Medicare
$47,557
Medicare patients
115
Services billed
475
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 47% | |
| Arthritis | 35% | |
| Depression | 28% | |
| Osteoporosis | 22% | |
| Diabetes | 17% | |
| Ischemic heart disease | 17% | |
| Atrial fibrillation | 17% | |
| Cancer | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Neurophysiology in California
Said Beydoun
Clinical Neurophysiology · Los Angeles, CA
Christopher Lock
Clinical Neurophysiology · Stanford, CA
Srikanth Muppidi
Clinical Neurophysiology · Stanford, CA
Mitchell Miglis
Clinical Neurophysiology · Stanford, CA
Michael Aminoff
Clinical Neurophysiology · San Francisco, CA
Safwan Jaradeh
Clinical Neurophysiology · Stanford, CA
Related records
Clinical Neurophysiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Neurophysiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.